Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Core Viewpoint - Neuphoria Therapeutics Inc. is addressing what it perceives as a deceptive campaign by Lynx1 Master Fund LP aimed at distracting shareholders from Lynx1's own shortcomings and lack of a clear plan [1][2][3] Company Positioning - Neuphoria emphasizes its commitment to transparency and value creation, urging stockholders to support its nominees while withholding votes for Lynx1's nominees [2][8] - The company is focused on developing therapies for neuropsychiatric disorders, with its lead drug candidate BNC210 targeting PTSD [9] Response to Lynx1's Claims - Neuphoria refutes Lynx1's assertions, presenting a detailed counterargument to each claim made by Lynx1, highlighting the company's strategic actions and board qualifications [4][5][6][7] - The company asserts that Lynx1's nominees lack the necessary experience and understanding of the company's needs, particularly in neuropsychiatric disorders [5][7] Strategic Review and Clinical Trials - Following the AFFIRM-1 Phase 3 clinical trial results, which missed primary and secondary endpoints, Neuphoria has halted development of BNC210 for social anxiety disorder and is conducting a strategic review [9] - The company is also engaged in partnerships, including one with Merck, to advance its pipeline for treating cognitive deficits in Alzheimer's disease [9] Board Composition and Governance - Neuphoria defends its current board's qualifications and experience, contrasting them with Lynx1's nominees, who are portrayed as lacking relevant expertise [6][7] - The company emphasizes the importance of having a strong cash balance and strategic oversight in navigating its clinical trials and corporate governance [6][7]